Did Biopharma Really Lose In TPP Trade Deal?
This article was originally published in PharmAsia News
After more than six years of intense efforts to lobby a group of Asia-Pacific trade ministers – a pact that eventually involved representatives from 12 nations – the innovator biopharmaceutical industry failed to get what it most wanted in the Trans-Pacific Partnership (TPP): 12 years of data exclusivity protection for biologics against biosimilars.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.